Combination of Plasma Beta Amyloid 42/40 and P-tau217 in the Assessment of Alzheimer’s Disease (S15.004)
Determine whether combining plasma beta amyloid 42/40 and p-tau217 could achieve ≥90 sensitivity and specificity in evaluating patients at an ADRC for possible Alzheimer’s disease (AD).
Authors
- Darren Weber (ORCID: https://orcid.org/0000-0002-4822-6661)
- Steven J. Taylor (ORCID: https://orcid.org/0000-0002-3020-5205)
- David E. Vaillancourt (ORCID: https://orcid.org/0000-0002-5663-6476)
- Michael K. Racke (ORCID: https://orcid.org/0000-0002-1231-4694)
- Melissa J. Armstrong (ORCID: https://orcid.org/0000-0002-2163-1907)
- Wei‐en Wang (ORCID: https://orcid.org/0000-0001-8555-9062)
- Sruti Rayaprolu (ORCID: https://orcid.org/0000-0002-5212-3745)
- Jesse C. DeSimone (ORCID: https://orcid.org/0000-0002-3823-8765)
- Matthew A. Stroh (ORCID: https://orcid.org/0000-0003-0096-8161)
- Glenn E. Smith (ORCID: https://orcid.org/0000-0003-1506-9484)
- Daniel Loewenstein
- Steve Coombes
- Ranjan Duara
- Rosie Cid Curiel
- Judy Z. Louie
Institutions
- University of Miami (US)
- University of Florida (US)
- Mount Sinai Medical Center (US)
- Quest Diagnostics (United Kingdom) (GB)
- Quest Diagnostics (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211589
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00